Heron Therapeuti Stock Performance
| HRTX Stock | USD 1.26 0.04 3.28% |
The company retains a Market Volatility (i.e., Beta) of 1.0, which attests to a somewhat significant risk relative to the market. Heron Therapeuti returns are very sensitive to returns on the market. As the market goes up or down, Heron Therapeuti is expected to follow. Heron Therapeuti right now retains a risk of 3.09%. Please check out Heron Therapeuti total risk alpha, accumulation distribution, as well as the relationship between the Accumulation Distribution and period momentum indicator , to decide if Heron Therapeuti will be following its current trending patterns.
Risk-Adjusted Performance
Weakest
Weak | Strong |
Over the last 90 days Heron Therapeuti has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of fairly strong basic indicators, Heron Therapeuti is not utilizing all of its potentials. The recent stock price disturbance, may contribute to short-term losses for the investors. ...more
Last Split Factor 1:20 | Last Split Date 2014-01-13 |
1 | Disposition of 13797 shares by Craig Collard of Heron Therapeuti subject to Rule 16b-3 | 10/17/2025 |
2 | Disposition of 34789 shares by Craig Collard of Heron Therapeuti subject to Rule 16b-3 | 10/31/2025 |
3 | Heron Therapeutics Q3 Earnings How Key Metrics Compare to Wall Street Estimates | 11/04/2025 |
4 | How cyclical is Heron Therapeutics Inc. stock compared to rivals - July 2025 Earnings Precise Buy Zone Identification - newser.com | 11/19/2025 |
5 | Heron Therapeutics, Inc. HRTX Shares Sold by Orchard Capital Management LLC | 11/28/2025 |
6 | Heron Therapeutics Announces Inclusion of APONVIE Injectable Emulsion in the Newly Released Fifth Consensus Guidelines for the Management of Postoperative Nause... | 12/04/2025 |
7 | Market Sentiment Around Loss-Making Heron Therapeutics, Inc. | 12/05/2025 |
8 | Heron Finance launches new private equity investing strategy for individual accredited investors and family offices | 12/09/2025 |
9 | Heron Therapeutics, Inc. Stock Catapults 27 percent Though Its Price And Business Still Lag The Industry | 12/16/2025 |
10 | Heron Finance review How Herons private credit investing strategy performed against peer funds | 12/23/2025 |
11 | International Private Equity Team Heron View Partners Announces Firm Launch | 12/30/2025 |
| Begin Period Cash Flow | 28.7 M | |
| Total Cashflows From Investing Activities | 18.7 M |
Heron Therapeuti Relative Risk vs. Return Landscape
If you would invest 128.00 in Heron Therapeuti on October 10, 2025 and sell it today you would lose (2.00) from holding Heron Therapeuti or give up 1.56% of portfolio value over 90 days. Heron Therapeuti is currently generating 0.0215% in daily expected returns and assumes 3.094% risk (volatility on return distribution) over the 90 days horizon. In different words, 27% of stocks are less volatile than Heron, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Heron Therapeuti Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Heron Therapeuti's investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Heron Therapeuti, and traders can use it to determine the average amount a Heron Therapeuti's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.0069
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | HRTX |
Based on monthly moving average Heron Therapeuti is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Heron Therapeuti by adding Heron Therapeuti to a well-diversified portfolio.
Heron Therapeuti Fundamentals Growth
Heron Stock prices reflect investors' perceptions of the future prospects and financial health of Heron Therapeuti, and Heron Therapeuti fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Heron Stock performance.
| Return On Equity | -24.09 | ||||
| Return On Asset | 0.0043 | ||||
| Profit Margin | (0.09) % | ||||
| Operating Margin | (0.11) % | ||||
| Current Valuation | 316.52 M | ||||
| Shares Outstanding | 183.36 M | ||||
| Price To Earning | (5.15) X | ||||
| Price To Book | 31.85 X | ||||
| Price To Sales | 1.49 X | ||||
| Revenue | 144.28 M | ||||
| Gross Profit | 102.78 M | ||||
| EBITDA | (5.06 M) | ||||
| Net Income | (13.58 M) | ||||
| Cash And Equivalents | 83.54 M | ||||
| Cash Per Share | 0.81 X | ||||
| Total Debt | 177.76 M | ||||
| Debt To Equity | 6.64 % | ||||
| Current Ratio | 1.77 X | ||||
| Book Value Per Share | 0.04 X | ||||
| Cash Flow From Operations | (22.53 M) | ||||
| Earnings Per Share | (0.09) X | ||||
| Market Capitalization | 231.04 M | ||||
| Total Asset | 233.15 M | ||||
| Retained Earnings | (1.92 B) | ||||
| Working Capital | 117.56 M | ||||
| Current Asset | 134.75 M | ||||
| Current Liabilities | 19.73 M | ||||
About Heron Therapeuti Performance
Evaluating Heron Therapeuti's performance through its fundamental ratios, provides valuable insights into its operational efficiency and profitability. For instance, if Heron Therapeuti has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Heron Therapeuti has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements. Please also refer to our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Days Of Inventory On Hand | 451.85 | 429.26 | |
| Return On Tangible Assets | (0.07) | (0.07) | |
| Return On Capital Employed | (0.09) | (0.10) | |
| Return On Assets | (0.07) | (0.07) | |
| Return On Equity | 0.46 | 0.49 |
Things to note about Heron Therapeuti performance evaluation
Checking the ongoing alerts about Heron Therapeuti for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Heron Therapeuti help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Heron Therapeuti may become a speculative penny stock | |
| Heron Therapeuti had very high historical volatility over the last 90 days | |
| Heron Therapeuti has a very high chance of going through financial distress in the upcoming years | |
| The company reported the previous year's revenue of 144.28 M. Net Loss for the year was (13.58 M) with profit before overhead, payroll, taxes, and interest of 102.78 M. | |
| Heron Therapeuti currently holds about 83.54 M in cash with (22.53 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.81. | |
| Heron Therapeuti has a very weak financial position based on the latest SEC disclosures | |
| Over 84.0% of the company shares are owned by institutional investors | |
| Latest headline from prnewswire.com: International Private Equity Team Heron View Partners Announces Firm Launch |
- Analyzing Heron Therapeuti's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Heron Therapeuti's stock is overvalued or undervalued compared to its peers.
- Examining Heron Therapeuti's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Heron Therapeuti's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Heron Therapeuti's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Heron Therapeuti's stock. These opinions can provide insight into Heron Therapeuti's potential for growth and whether the stock is currently undervalued or overvalued.
Additional Tools for Heron Stock Analysis
When running Heron Therapeuti's price analysis, check to measure Heron Therapeuti's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Heron Therapeuti is operating at the current time. Most of Heron Therapeuti's value examination focuses on studying past and present price action to predict the probability of Heron Therapeuti's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Heron Therapeuti's price. Additionally, you may evaluate how the addition of Heron Therapeuti to your portfolios can decrease your overall portfolio volatility.